European Urology

Viewing slides 1-6 of 8

• S0302-2838(08)01212-8.title drag remove slide sort drag into slide Title Can Tyrosine Kinase Inhibitors be Discontinued in Patients with Metastatic Renal Cell Carcinoma and a Complete Response to Treatment? A Multicenter Retrospective Analysis
  
  Manfred Johannsen a, Anne ... Can Tyrosine Kinase Inhibitors be Discontinued in Patients with Metastatic Renal Cell Carcinoma and ... Zoom
• S0302-2838(08)01212-8.introduction drag remove slide sort drag into slide Introduction • Treatment with antiangiogenic agents such as tyrosine kinase inhibitors (TKIs) for metastatic renal cell carcinoma (mRCC) is characterized by substantial response rates, but also considerable ... • Treatment with antiangiogenic agents such as tyrosine kinase inhibitors (TKIs) for ... Zoom
• 7758 drag remove slide sort drag into slide Progression of metastasis in patient 1: (a) Left pulmonary metastasis before ... Zoom read this article »
• 7760 drag remove slide sort drag into slide Progression of metastasis in patient 3: (a) Right pulmonary metastasis in ... Zoom read this article »
• 7762 drag remove slide sort drag into slide Remission of metastases in patient 12: (a) Right pulmonary metastasis before ... Zoom read this article »
• S0302-2838(08)01212-8.materials_and_methods drag remove slide sort drag into slide Materials and methods • The objective of this study was to evaluate whether TKIs can be discontinued in these selected patients with mRCC
  
  • A retrospective analysis of medical records and imaging studies was ... • The objective of this study was to evaluate whether TKIs can be discontinued in these ... Zoom

Viewing slides 1-6 of 8